miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44

• Published in: Molecular therapy. Nucleic acids Vol. 35; no. 1; p. 102091
• Main Authors: Wu, Shang-Gin, Chang, Tzu-Hua, Tsai, Meng-Feng, Liu, Yi-Nan, Huang, Yen-Lin, Hsu, Chia-Lang, Jheng, Han-Nian, Shih, Jin-Yuan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 12.03.2024; American Society of Gene & Cell Therapy; Elsevier
• Subjects: CD44; EGFR; EMT; epidermal growth factor receptor; epithelial-to-mesenchymal transition; miR-204; MT: Noncoding RNAs; Original; osimertinib resistance; stemness; TKI; tyrosine kinase inhibitor; miR-204; TKI; epidermal growth factor receptor; stemness; tyrosine kinase inhibitor; MT: Noncoding RNAs; EMT; CD44; osimertinib resistance; EGFR; epithelial-to-mesenchymal transition

Osimertinib is an effective treatment option for patients with advanced non-small cell lung cancer (NSCLC) with EGFR activation or T790M resistance mutations; however, acquired resistance to osimertinib can still develop. This study explored novel miRNA–mRNA regulatory mechanisms that contribute to...